163 related articles for article (PubMed ID: 16632010)
21. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis.
Montenegro J; Cornago I; Gallardo I; García-Ledesma P; Hernando A; Martinez I; Muñoz RI; Romero MA
Nephrology (Carlton); 2012 Jan; 17(1):26-31. PubMed ID: 22022934
[TBL] [Abstract][Full Text] [Related]
23. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
24. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
[TBL] [Abstract][Full Text] [Related]
25. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
26. Future role of calcimimetics in end-stage renal disease.
Goodman WG; Turner SA
Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
[TBL] [Abstract][Full Text] [Related]
27. Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Drüeke TB; Landais P
Am J Kidney Dis; 2006 Jun; 47(6):1083; author reply 1083-4. PubMed ID: 16731305
[No Abstract] [Full Text] [Related]
28. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
30. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
31. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Negri AL; Slatopolsky EA
Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
33. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?
Goodman WG
Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):355-60. PubMed ID: 15931004
[TBL] [Abstract][Full Text] [Related]
34. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
Lindberg JS
Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
[TBL] [Abstract][Full Text] [Related]
35. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
36. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
37. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
38. Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis.
Drüeke TB
Nephrol Dial Transplant; 2002; 17 Suppl 11():20-2. PubMed ID: 12386252
[TBL] [Abstract][Full Text] [Related]
39. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]